Company Legal and Accounting Team Focuses on SEC Filings
YUCAIPA, Calif., Oct. 30, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has hired Anton & Chia, LLP as the new auditing firm after dismissing Child, Van Wagoner and Bradshaw on Wednesday of this week.
The Irvine-California based Anton & Chia's team of professionals consist of certified public accountants that are able to assist Ingen with the 10-KSB ending May 31, 2009 and future filings. This firm has over 40 years of experience working with small to middle market companies and understands Ingen's needs. Anton & Chia are licensed CPAs in the following states: California, Colorado, Florida and New York and have a professional staff that are fluent in speaking and writing Mandarin, Cantonese, Italian, and Spanish. As specialists in the realm of public company accounting and reporting, the professionals of Anton & Chia, LLP go to great lengths to ensure the accuracy and timeliness of required financial reporting, compliance and transaction-related issues for our public clients. With the immediate needs of Ingen, Anton & Chia will assist the company in preparing for and meeting obligations in the increasingly complex regulatory environment of public companies in order to comply with rules of the U.S. Securities and Exchange Commission (SEC) and obligations promulgated by the Sarbanes-Oxley Act of 2002.
"We found a firm that can meet our filing schedule. Our legal and accounting team is working very close with the SEC and the new auditors to complete and file the 10-KSB ending May 31, 2009 and subsequent 10-Q's to bring current our filing obligations," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
http://ancsecservices.com/
www.ingen-tech.com
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment